<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.eurjchem.com/lib/pkp/xml/oai2.xsl" ?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/
		http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
	<responseDate>2026-05-25T00:40:09Z</responseDate>
	<request identifier="oai:ojs.www.eurjchem.com:article/596" metadataPrefix="oai_dc" verb="GetRecord">https://www.eurjchem.com/index.php/eurjchem/oai</request>
	<GetRecord>
		<record>
			<header>
				<identifier>oai:ojs.www.eurjchem.com:article/596</identifier>
				<datestamp>2012-08-06T14:50:19Z</datestamp>
				<setSpec>eurjchem:ART</setSpec>
				<setSpec>driver</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">In-vitro cytotoxic and radiosensitizing evaluation of novel 2-pyridone, isoquinoline, chromene and chromenopyridone derivatives</dc:title>
	<dc:creator>Al-Said, Mansour Sulaiman</dc:creator>
	<dc:creator>El-Gazzar, Marwa Galal</dc:creator>
	<dc:creator>Ghorab, Mostafa Mohammed</dc:creator>
	<dc:subject xml:lang="en-US">Cytotoxic</dc:subject>
	<dc:subject xml:lang="en-US">Chromene</dc:subject>
	<dc:subject xml:lang="en-US">2-Pyridone</dc:subject>
	<dc:subject xml:lang="en-US">Isoquinoline</dc:subject>
	<dc:subject xml:lang="en-US">Radiosensitizing</dc:subject>
	<dc:subject xml:lang="en-US">Chromenopyridone</dc:subject>
	<dc:description xml:lang="en-US"> On the account of the reported anticancer activity of 2-pyridone, a new series of ethyl-1,6-dihydropyridine-3-carboxylate (4a-j), 1-oxo-1,2-dihydroisoquinoline-7-carbonitrile (6a-h), 2H-chromene (7,8) and 3H-chromeno[3,4-c]pyridone derivatives (9,10) were synthesized and tested for in-vitro anticancer activity against Ehrlich Ascites Carcinoma (EAC) cell line and human liver cell line (HEPG2). The structures of the synthesized compounds were confirmed by analytical and spectral data. Furthermore, radiosensitization study was performed for the most potent compounds (4a, 4d, 6a, 6c, 6e and 10). </dc:description>
	<dc:publisher xml:lang="en-US">Atlanta Publishing House LLC</dc:publisher>
	<dc:date>2012-06-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://www.eurjchem.com/index.php/eurjchem/article/view/596</dc:identifier>
	<dc:identifier>10.5155/eurjchem.3.2.228-234.596</dc:identifier>
	<dc:source xml:lang="en-US">European Journal of Chemistry; Vol. 3 No. 2 (2012): June 2012; 228-234</dc:source>
	<dc:source>2153-2257</dc:source>
	<dc:source>2153-2249</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://www.eurjchem.com/index.php/eurjchem/article/view/596/PDF</dc:relation>
</oai_dc:dc>
			</metadata>
		</record>
	</GetRecord>
</OAI-PMH>
